ArticleJournal of gastroenterology2010
Rapid endoscopic improvement is important for 1-year avoidance of colectomy but not for the long-term prognosis in cyclosporine A treatment for ulcerative colitis.
Article in Journal of gastroenterology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 2 syntheses or guidelines pooled it, 44 citations in OpenAlex.
- Predictors for colectomy in patients with acute severe ulcerative colitis: a systematic review and meta-analysis.BMJ open gastroenterology · 2024Pooled it
- Efficacy and Safety of Tacrolimus Therapy for Active Ulcerative Colitis; A Systematic Review and Meta-analysis.Journal of Crohn's & colitis · 2016Pooled it
- Short- and longevity outcome of cyclosporin rescue therapy in severe ulcerative colitis refractory to intravenous corticosteroid treatment.Therapeutic advances in gastroenterology · 2025Article
- Early change in serum leucine-rich α-2-glycoprotein predicts clinical and endoscopic response in ulcerative colitis.Intestinal research · 2024Article
- A real-world disproportionality analysis of cyclosporine from the FDA Adverse Event Reporting System (FAERS) database.Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologica · 2024Article
- Acute Severe Ulcerative Colitis: Optimal Strategies for Drug Therapy.Gut and liver · 2023Review
- Review article: latent tuberculosis in patients with inflammatory bowel diseases receiving immunosuppression-risks, screening, diagnosis and management.Alimentary pharmacology & therapeutics · 2022Review
- Recent trends and future directions for the medical treatment of ulcerative colitis.Clinical journal of gastroenterology · 2016Review
- Correlation between Histological Activity and Endoscopic, Clinical, and Serologic Activities in Patients with Ulcerative Colitis.Gastroenterology research and practice · 2016Article
- Azathioprine is essential following cyclosporine for patients with steroid-refractory ulcerative colitis.World journal of gastroenterology · 2015Article
- Long-term outcome of cyclosporin rescue therapy in acute, steroid-refractory severe ulcerative colitis.United European gastroenterology journal · 2014Article
- Pre- and posttherapy assessment of intestinal soluble mediators in IBD: where we stand and future perspectives.Mediators of inflammation · 2013Review
- Role of surgery in severe ulcerative colitis in the era of medical rescue therapy.World journal of gastroenterology · 2012Review
- Update on the management of ulcerative colitis.Current gastroenterology reports · 2011Review
- The use of traditional and newer calcineurin inhibitors in inflammatory bowel disease.Journal of gastroenterology · 2011Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundIntravenous (IV) cyclosporine A (CSA) is one of the treatments of choice for patients with steroid-refractory severe ulcerative colitis (UC). In this study, we evaluated the overall experience with CSA treatment in UC patients, from their initial response to long-term prognosis.
methodsThe medical records of 72 patients admitted to our hospital with a severe UC flare-up and treated with IV CSA between November 1996 and October 2008 were reviewed retrospectively. The initial response to CSA was assessed using a clinical activity index, and colectomy was assigned as the endpoint for the long-term prognosis.
resultsOverall, 53 of 72 (73.6%) patients responded initially to CSA. We could not determine any specific parameters that predicted an initial response. A life-table analysis for all patients revealed that 54.4% of patients required a colectomy within 11 years. The long-term risk of surgery was associated with a shorter disease duration, history of adverse reactions against medications and lack of immunomodulator use. In addition, endoscopic improvement at day 14 was associated with colectomy at 1 year, but not with the long-term prognosis.
conclusionsAlthough CSA can exert high initial efficacy for severe attacks of UC, >50% of patients who relapse require a colectomy. Specifically, mucosal healing evaluated by endoscopy was associated with the 1-year colectomy rate. In contrast, a history of adverse drug reactions was correlated with the long-term colectomy rate. Therefore, we propose that treatment of severe UC with CSA requires consideration of both initial remission and long-term maintenance as management goals.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.